athenahealth buys SaaS provider for $22.3M

Jeff Byers | | Health Exec | Economics
Watertown, Mass.-based athenahealth, a provider of Internet-based business services for physician practices, has signed a definitive agreement to acquire Anodyne Health Partners, which develops Software-as-a-Service (SaaS) business applications for healthcare providers. The transaction, including a cash payment of $22.3 million, is expected to close this month.

Anodyne currently services large and enterprise medical group clients with a proprietary Web-based business intelligence software platform, Anodyne Intelligence, and related services, athenahealth said. The platform allows an organization to view all facets of its revenue cycle and to access and extract critical operational and administrative information from various data systems.

Terms of the merger agreement include a cash payment of $22.3 million with the potential for additional consideration of up to $7.7 million, based on the achievement of certain business and financial milestones. The Alpharetta, Ga.-based Anodyne will operate as a separate unit of athenahealth with its own brand identity, according to athenahealth.

Jeff Byers

Related Content

Walgreens confirms $10B sale to PE, as part of $24B transaction
5 ways AI can help make healthcare more affordable for everyone
More than 1,000 hospitals earn $700M opioid crisis judgment
Building a successful CCTA program: Physicians and healthcare executives to share advice
VA planning 83,000 layoffs as part of restructuring
Boston Scientific enters renal denervation market with acquisition worth up to $540M

Around the web

Cardiovascular Business
Boston Scientific enters renal denervation market with acquisition worth up to $540M

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
FDA announces catheter recall for Johnson & Johnson PFA system due to stroke risk

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.